99
Views
29
CrossRef citations to date
0
Altmetric
Review

Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus

, &
Pages 351-363 | Published online: 10 Jan 2014

References

  • Anhalt GJ, Kim SC, Stanley JR et al. Paraneoplastic pemphigus, an autoimmune disease associated with neoplasia. N. Engl. J. Med.323, 1729–1735 (1990).
  • Liu AY, Valenzuela R, Helm TN, Camisa C, Melton AL, Bergfeld WF. Indirect immunofluorescence on rat bladder transitional epithelium: a test with high specificity for paraneoplastic pemphigus. J. Am. Acad. Dermatol.28, 696–699 (1993).
  • Anhalt GJ. Paraneoplastic pemphigus. J. Invest. Dermatol. Symp. Proc.9, 29–33 (2004).
  • Joly P, Richard C, Gilbert D et al. Sensitivity and specificity of clinical, histologic and immunologic features in the diagnosis of paraneoplastic pemphigus. J. Am. Acad. Dermatol.43, 619–626 (2000).
  • Nguyen VT, Ndoye A, Bassler KD et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome. Arch. Dermatol.137, 193–207 (2001).
  • Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J. Am. Acad. Dermatol.40, 649–671 (1999).
  • Schlesinger T, McCarron K, Camisa C, Anhalt G. Paraneoplastic pemphigus occurring in a patient with B-cell non-Hodgkin’s lymphoma. Cutis61, 94–96 (1998).
  • Plumb R, Doolittle GC. Paraneoplastic pemphigus in a patient with non-Hodgkin’s lymphoma. Am. J. Hematol.52, 58–59 (1996).
  • Marzano AV, Grammatica A, Cozzani E, Terracina M, Berti E. Paraneoplastic pemphigus. A report of two cases associated with chronic B-cell lymphocytic leukaemia. Br. J. Dermatol.145, 127–131(2001).
  • Jansen T, Plewig G, Anhalt GJ. Paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman’s tumor. Dermatology190, 245–250 (1995).
  • Lemon MA, Weston WL, Huff JC. Childhood paraneoplastic pemphigus associated with Castleman’s tumour. Br. J. Dermatol.136, 115–117 (1997).
  • Kim SC, Chang SN, Lee IJ et al. Localized mucosal involvement in a young patient with paraneoplastic pemphigus associated with Castleman’s tumour. Br. J. Dermatol.138, 667–671 (1998).
  • Wolff H, Kunte C, Messer G et al. Paraneoplastic pemphigus with fatal pulmonary involvement in a woman with a mesenteric Castleman tumour. Br. J. Dermatol.140, 313–316 (1999).
  • Lee IJ, Kim SC, Kim HS et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma arising from Castleman’s tumor. J. Am. Acad. Dermatol.40, 294–297 (1999).
  • Irsutti M, Paul JL, Selves J, Railhac JJ. Castleman disease: CT and MR imaging features of a retroperitoneal location in association with paraneoplastic pemphigus. Eur. Radiol.9, 1219–1221 (1999).
  • Chorzelski T, Hashimoto T, Maciejewska B, Amagai M, Anhalt GJ, Jablonska S. Paraneoplastic pemphigus associated with Castleman’s tumor, myasthenia gravis and bronchiolitis obliterans. J. Am. Acad. Dermatol.41, 393–400 (1999).
  • Hsiao CJ, Hsu MML, Lee JYY, Chen WC, Hsieh WC. Paraneoplastic pemphigus in association with a retroperitoneal Castleman’s disease presenting with a lichen planus pemphigoides-like eruption. A case and review of literature. Br. J. Dermatol.144, 372–376 (2001).
  • Chin AC, Stich D, White FV, Radhacrishnan J, Holterman MJ. Paraneoplastic pemphigus and bronchiolitis obliterans associated with a mediastinal mass: a rare case of Castleman’s disease with respiratory failure requiring lung transplantation. J. Pediatr. Surg.36, E22 (2001).
  • Fujimoto W, Kanehiro A, Kuwamoto-Hara K et al. Paraneoplastic pemphigus associated with Castleman’s disease and asymptomatic bronchiolitis obliterans. Eur. J. Dermatol.12, 355–359 (2002).
  • Wang L, Bu D, Yang Y, Chen X, Zhu H. Castleman’s tumours and production of autoantibody in paraneoplastic pemphigus. Lancet363, 525–531 (2004).
  • Hinterhuber G, Drach J, Riedl E et al. Paraneoplastic pemphigus in association with hepatocellular carcinoma. J. Am. Acad. Dermatol.49, 538–540 (2003).
  • Niimi Y, Kawana S, Hashimoto T, Kusunoki T. Paraneoplastic pemphigus associated with uterine carcinoma. J. Am. Acad. Dermatol.48, S69–S72 (2003).
  • Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis or non-hematologic malignancy and oral mucosal manifestations. Oral. Oncol.40(6), 553–562 (2004).
  • Anhalt GJ. Paraneoplastic pemphigus. Adv. Dermatol.12, 77–96 (1997).
  • Younus J, Ahmed AR. The relationship of pemphigus to neoplasia. J. Am. Acad. Dermatol.23, 498–502 (1990).
  • De Saint PG, Albes B, Bayle P, Lamant L, Bazex J. Cutaneous T-cell lymphoma, cutaneous hyperpigmentation and paraneoplastic pemphigus. Ann. Dermatol. Venereol.129, 896–900 (2002).
  • Marzano AV, Vezzoli P, Mariotti F, Boneschi V, Caputo R, Berti E. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma and Castleman disease. Br. J. Dermatol.153(1), 214–215 (2005).
  • Park GT, Lee JH, Yun SJ, Lee SC, Lee JB. Paraneoplastic pemphigus without an underlying neoplasm. Br. J. Dermatol.156, 563–566 (2007).
  • Ostezan LB, Fabre VC, Caughman SW, Swerlick RA, Korman NJ, Callen JP. Paraneoplastic pemphigus in the absence of a known neoplasm. J. Am. Acad. Dermatol.33, 312–315 (1995).
  • Mimouni D, Anhalt GJ, Lazarova Z et al. Paraneoplastic pemphigus in children and adolescents. Br. J. Dermatol.147, 725–732 (2002).
  • Lane JE, Woody C, Davis LS, Guill MF, Jerath RS. Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: case report and review of the literature. Pediatrics114, 513–516 (2004).
  • Wang J, Bu DF, Li T et al. Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. Br. J. Dermatol.153, 558–564 (2005).
  • Bowen GM, Peters NT, Fivenson DP et al. Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenetic trigger of epitope spreading? Arch. Dermatol.136, 652–656 (2000).
  • Chan LS. Epitope spreading in paraneoplastic pemphigus: autoimmune induction in antibody-mediated blistering skin diseases. Arch. Dermatol.136, 663–664 (2000).
  • Zhu X, Zhang B. Paraneoplastic pemphigus. J. Dermatol.34, 503–511 (2007).
  • Zhang B, Zheng R, Wang J, Bu D, Zhu X. Epitopes in the linker subdomain region of envoplakin recognized by autoantibodies in paraneoplastic pemphigus patients. J. Invest. Dermatol.126, 832–840 (2006).
  • Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur. J. Immunol.31, 1122–1131 (2001).
  • Reich K, Brinck U, Letschert M et al. Graft-versus-host-disease-like immunophenotype and apoptotic keratinocyte in paraneoplastic pemphigus. Br. J. Dermatol.141, 739–746 (1999).
  • Powell AM, Albert S, Oyama N, Sakuma-Oyama Y, Bhogal B, Black MM. Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans. JEADV18, 360–364 (2004).
  • Gooptu C, Littlewood TJ, Frith P, Lyon CC, Carmichael AJ, Oliwiecki S. Paraneoplastic pemphigus: an association with fludarabine? Br. J. Dermatol.144(66), 1255–1261 (2001).
  • Menenakos C, Braumann C, Hartmann C, Jacobi CA. Retroperitoneal Castleman’s tumor and paraneoplastic pemphigus: report of a case and review of the literature. World J. Surg. Oncol.5, 45 (2007).
  • Nousari HC, Deterding R, Wojtczack H et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N. Engl. J. Med.340, 1406–1410 (1999).
  • Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman’s disease. Br. J. Dermatol.149, 1143–1151 (2003).
  • Cummins DL, Mimouni D, Tzu J, Owens N, Anhalt GJ, Meyerle JH. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies J. Am. Acad. Dermatol.56, 153–159 (2007).
  • Hoffman MA, Qiao X, Anhalt GJ. CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman’s disease. N. Engl. J. Med.24(349), 407–408 (2003).
  • Sun H, Wang R, Bin H et al. Localized Castleman’s disease with paraneoplastic pemphigus and pulmonary involvement, clinical features and histopathology. Zhonghua Yi Xue Za Zhi82, 530–533 (2002).
  • Heymann WR. Paraneoplastic autoimmune multiorgan syndrome. J. Am. Acad. Dermatol.51, 631–632 (2004).
  • Wang J, Zhu X, Li R et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch. Dermatol.141, 1285–1293 (2005).
  • Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fisher A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet358, 1511–1513 (2001).
  • Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum.44, 2836–2840 (2001).
  • Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood98, 952–957 (2001).
  • Grillo-Lopez AJ, White CA, Dallaire BK et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr. Pharm. Biotechnol.1, 1–9 (2000).
  • Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed. Pharmacother.58, 299–309 (2004).
  • Byrd JC, Waselenko JK, Maneatis TJ et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol.17, 791–795 (1999).
  • Lowndes S, Darby A, Mead G et al. Stevens–Johnson syndrome after treatment with rituximab. Ann. Oncol.13, 1948–1950 (2002).
  • Borradori L, Lombardi T, Samson J et al. Anti-CD20 monoclonal antibody (rituxiamb) for refractory erosive stomatits secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus. Arch. Dermatol.137, 269–272 (2001).
  • Heizmann M, Itin P, Wernli M, Borradori L, Bargentzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am. J. Hematol.66, 142–144 (2001).
  • Barnadas MA, Roe E, Brunet S et al. Therapy of paraneoplastic pemphigus with rituximab: a case report and review of literature. JEADV20, 69–74 (2006).
  • Vecchietti G, Kerl K, Hügli A, Samson J, Borradori L. Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus. Br. J. Dermatol.148, 823–842 (2003).
  • Ahmed Razzaque A, Avram MM, Duncan LM. Case 23–2003: a 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. N. Engl. J. Med.349, 382–391 (2003).
  • Van Rossum MM, Verhaegen NT, Jonkman MF et al. Follicular non-Hodgkin’s lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities. Leukemia Lymphoma45(11), 2327–2332 (2004).
  • Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J. Drugs Dermatol.2, 564–567 (2003).
  • Hoque SR, Black MM, Cliff S. Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin’s lymphoma treated with rituximab: a third case resistant to rituximab therapy. Clin. Exp. Dermatol.32, 172–175 (2007).
  • Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology55, 1062–1063 (2000).
  • Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann. Intern. Med.133, 275–279 (2000).
  • Shvidel L, Klepfish A, Berrebi A. Succesful treatment with rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin’s lymphoma. Am. J. Hematol.67, 213–219 (2001).
  • Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology214, 310–318 (2007).
  • Salopeck TG, Logsetty S, Tredger EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J. Am. Acad. Dermatol.47, 785–788 (2002).
  • España E, Fernández-Galar M, Lloret P, Sánchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J. Am. Acad. Dermatol.50, 974–976 (2004).
  • Arin MJ, Hunzelmann N. Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus –an update. Eur. J. Dermatol.15, 224–230 (2005).
  • Niedermeier A, Worl P, Barth S, Schuler G, Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur. J. Dermatol.16, 266–270 (2006).
  • Niedermeier A, Eming R, Pfutze M et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibody). Arch. Dermatol.143, 192–198 (2007).
  • Schmidh E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br. J. Dermatol.156, 352–356 (2007).
  • Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med.355, 1772–1779 (2006).
  • Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. N. Eng. J. Med.357, 545–552 (2007).
  • Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and review of the literature. Arch. Dermatol.143(8), 1033–1038 (2007).
  • Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol.14, 520–533 (2003).
  • Lehrnbecher T. [Intravenous immunoglobulins in the prevention of infection in children with hematologic–oncologic diseases.] Klin. Padiatr.213(Suppl. 1), A103–A105 (2001).
  • Sullivan KM, Kopecky HJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N. Engl. J. Med.323, 705–712 (1990).
  • Belgi AS, Azeez M, Hoyle C, Willams RE. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br. J. Dermatol.153, 620–625 (2005).
  • Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Clin. Exp. Dermatol.28, 366–368 (2003).
  • Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR. Correlation of peptide specificity and IgG subclass with pathogenic and non-pathogenic autoantibodies in pemphigus vulgaris. Proc. Natl Acad. Sci. USA92, 5239–5243 (1995).
  • Harris DP, Haynes L, Sayles PC et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol.6, 475–482 (2006).
  • Hertl M, Veldman C. T cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun. Rev.2, 278–283 (2003).
  • Schmidt E, Hunzelmann N, Zillikens D, Bröcker EB, Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clin. Exp. Dermatol.31, 503–508 (2006).
  • Skok J, Poudrier J, Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J. Immunol.163, 4284–4291 (1999).
  • Camisa C, Helm TN, Liu YC et al. Paraneoplastic pemphigus: a report of three cases including one long term survivor. J. Am. Acad. Dermatol.27, 547–553 (1992).
  • Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasias-induced autoimmune disease. Arch. Dermatol.129, 883–885 (1993).
  • Tóth GG, van der Meer JB, Jonkman MF. Dexamethasone pulse therapy in pemphigus. J. Eur. Acad. Dermatol. Venereol.16(6), 607–611 (2002).
  • Dega H, Laporte JL, Joly P, Gabarre J, André C. Paraneoplastic pemphigus associated with Hodgkins disease. Br. J. Dermatol.138, 196–198 (1998).
  • Martinez De Pablo MI, Iranzo P, Mascara JM, Llambrich A, Baradad M, Herrero C. Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone. Acta Dermatol. Venereol.85, 233–235 (2005).
  • Beutner EH, Pelton S, Hashimoto T et al. A nonfatal case and 2 fatal cases of paraneoplastic pemphigus: can complement indirect immunofluorescent test help to identify fatal ‘group A’ paraneoplastic pemphigus cases? J. Am. Acad. Dermatol.47, 841–851 (2002).
  • Williams JV, Marks JG JR, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br. J. Dermatol.142, 506–508 (2000).
  • Herzberg MS, Schiffer M, Sullivan J, Stapleton K. Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin’s lymphoma: significant responses to cyclophosphamide and prednisolone. Am. J. Hematol.63, 105–106 (2000).
  • Becker R, Bastian C, Wesselmann U, Karl S, Hamm H, Bröcker EB. Paraneoplastic pemphigus treated with dexamethasone/cyclophosphamide pulse therapy. Eur. J. Dermatol.8, 551–553 (1998).
  • Perniciaro C, Kuechle M, Colón-Otero G, Raymond MG, Spear KL, Pittelkow MR. Paraneoplastic pemphigus: a case of prolonged survival. Mayo Clin. Proc.69, 851–855 (1994).
  • Nanda M, Nanda A, Al-Sabah H, Dvorak R, Alsaleh QA. Paraneoplastic pemphigus in association with B-cell lymphocytic leucemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone. Int. J. Dermatol.46, 767–769 (2007).
  • Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J. Am. Acad. Dermatol.40, 750–754 (1999).
  • Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with Mycophenolic acid. J. Dermatol. Treat.17, 370–376 (2006).
  • Proby C, Fujii Y, Owaribe K, Nishikawa T, Amagai M. Human autoantibodies against HD1/plectin in paraneoplastic pemphigus. J. Invest. Dermatol.112, 153–156 (1999).
  • Izaki S, Yoshizawa Y, Kitamura K et al. Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis. Br. J. Dermatol.134, 987–989 (1996).
  • Braess J. Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin’s lymphoma of B-cell type (B-NHL). Ann. Hematol.75, 227–230 (1997).
  • Hohwy T, Bang K, Steiniche T, Anker Peterslund N, D’Amore F. Alemtuzumab-induced remission of both severe paraneoplstic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia. Eur. J. Haematol.73, 206–209 (2004).
  • Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med.350, 2572–2581 (2004).
  • Dupuy A, Viguier M, Bédane C et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch. Dermatol.140, 91–96 (2004).
  • Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann. Rheum. Dis.61, 922–924 (2002).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.